Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients

被引:16
作者
Akhlaghi, F
Gonzalez, L
Trull, AK
机构
[1] Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Clin Pharmacokinet Res Lab, Kingston, RI 02881 USA
[2] Univ Rhode Isl, Dept Comp Sci & Stat, Kingston, RI 02881 USA
[3] Papworth Hosp, Dept Pharmacol, Cambridge CB3 8RE, England
关键词
D O I
10.1016/j.healun.2005.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The objective of this study was to investigate the relationship between cyclosporine (CsA) pharmacokinetic parameters and clinical outcomes after lung transplantation. Methods: Data from 48 lung or heart/lung transplant recipients originally recruited to a randomized, prospective clinical trial of Sandimmune vs Neoral and followed for 12 months were included in this study. CsA dosing was based on the trough concentration. CsA concentrations at 0 (CO), 2 (C2), and 6 (C6) hours post-dosing were obtained at 1, 2, 3, 4, 13, 26, 39, and 52 post-operative weeks. Based on their average C2 levels in the first post-transplant month, patients were stratified retrospectively into Low C2 (< 1,000 mu g/liter, n = 18), Intermediate C2 (1,000-1,500 mu g/liter, n = 16) and High C2 (> 1,500 mu g/liter, n = 14) Groups. Results: Cyclosporine C2 was the best single-point determinant (r(2) = 0.934) for area-under-the-concentration-time curve (AUC(0-6 hours)) compared with CO (r(2) = 0.267) or C0 (r(2) = 0.304). The mean +/- SD values of CsA C2 and AUC(0 to 6 hours) in the first year post-transplant were significantly lower in patients with > 2 rejection episodes compared with those with <= 2 rejection episodes (C2: 875 +/- 546 mu g/liter vs 1,114 +/- 633 mu g/liter, p = 0.01; AUC(0-6 hours): 4,036 +/- 1,904 mu g X hour/liter vs 4,870 +/- 2,182 mu g X hour/liter; p = 0.01) whereas CO and C6 did not differ. Patients in the Intermediate C2 Group were free from rejection episodes for a significantly longer duration (p < 0.001) and had significantly higher predicted forced expiratory volume in I second (%) values (p < 0.001) compared with the Low and High C2 Groups. The percentage of increase in serum creatinine concentration by the end of first month post-transplant was significantly higher in the Intermediate C2 Group (p < 0.003). Conclusions: CsA C2 concentrations correlated better with the incidence of multiple rejections after lung transplantation than did CO or C6. C2 concentrations between 1,000 and 1,500 mu g/liter within the first post-operative month may be associated with better graft outcomes and improved pulmonary function and worsened renal function.
引用
收藏
页码:2120 / 2128
页数:9
相关论文
共 28 条
  • [1] Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients
    Belitsky, P
    Dunn, S
    Johnston, A
    Levy, G
    [J]. CLINICAL PHARMACOKINETICS, 2000, 39 (02) : 117 - 125
  • [2] Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients .2. Blood cyclosporine concentrations and other risk factors for lung allograft rejection
    Best, NG
    Tan, KKC
    Trull, AK
    Spiegelhalter, DJ
    Stewart, S
    Wallwork, J
    [J]. TRANSPLANTATION, 1996, 62 (10) : 1436 - 1441
  • [3] Clinical benefit of neoral dose monitoring with cyclosporine 2-HR post-dose levels compared with trough levels in stable heart transplant patients
    Cantarovich, M
    Elstein, E
    de Varennes, B
    Barkun, JS
    [J]. TRANSPLANTATION, 1999, 68 (12) : 1839 - 1842
  • [4] Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling
    Clase, CM
    Mahalati, K
    Kiberd, BA
    Lawen, JG
    West, KA
    Fraser, AD
    Belitsky, P
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) : 789 - 795
  • [5] Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients
    Cole, E
    Naham, N
    Cardella, C
    Cattran, D
    Fenton, S
    Hamel, J
    O'Grady, C
    Smith, R
    [J]. TRANSPLANTATION, 2003, 75 (12) : 2086 - 2090
  • [6] Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms
    David, OJ
    Johnston, A
    [J]. THERAPEUTIC DRUG MONITORING, 2001, 23 (02) : 100 - 114
  • [7] Neoral C2 monitoring in pediatric liver transplant recipients
    Dunn, S
    Falkenstein, K
    Cooney, G
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3094 - 3095
  • [8] Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation
    Glanville, AR
    Morton, JM
    Aboyoun, CL
    Plit, ML
    Malouf, MA
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (10) : 1170 - 1174
  • [9] Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection -: Results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)
    Grant, D
    Kneteman, N
    Tchervenkov, J
    Roy, A
    Murphy, G
    Tan, A
    Hendricks, L
    Guilbault, N
    Levy, G
    [J]. TRANSPLANTATION, 1999, 67 (08) : 1133 - 1137
  • [10] Keown P, 2001, TRANSPLANTATION, V72, P1024